Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clinuvel Pharmaceuticals' : Net Profit Jumps 64% on Higher Drug Demand

08/26/2021 | 04:02am EDT


ę MT Newswires 2021
All news about CLINUVEL PHARMACEUTICALS LIMITED
10/21CLINUVEL PHARMACEUTICALS : Doses First Patient of Xeroderma Pigmentosum in DNA Repair Prog..
MT
10/21CLINUVEL PHARMACEUTICALS : First Patient Treated in CLINUVEL DNA Repair Study
PU
10/21Clinuvel Pharmaceuticals Limited Announces First Patient Treated in Clinuvel DNA Repair..
CI
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
10/05CLINUVEL PHARMACEUTICALS : Secures Clearances for Phase Two Study of DNA Repair Drug
MT
10/04CLINUVEL PHARMACEUTICALS : Progresses DNA Repair Program
PU
10/04Clinuvel Pharmaceuticals Limited Receives the Necessary Regulatory and Ethics Committee..
CI
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
More news
Financials
Sales 2022 64,6 M 48,4 M 48,4 M
Net income 2022 30,9 M 23,1 M 23,1 M
Net cash 2022 108 M 80,8 M 80,8 M
P/E ratio 2022 64,2x
Yield 2022 0,11%
Capitalization 1 934 M 1 450 M 1 448 M
EV / Sales 2022 28,3x
EV / Sales 2023 19,5x
Nbr of Employees -
Free-Float 79,2%
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 39,14 AUD
Average target price 33,92 AUD
Spread / Average Target -13,3%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED75.36%1 447
CSL LIMITED4.38%100 729
WUXI BIOLOGICS (CAYMAN) INC.14.49%61 841
SAMSUNG BIOLOGICS CO.,LTD.6.17%49 427
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.8.14%39 464